Safety and efficacy of 0.02% and 0.01% atropine on controlling myopia progression: a 2-year clinical trial

Abstract Four hundred myopic children randomly received atropine 0.02% (n = 138) or 0.01% (n = 142) in both eyes once-nightly or only wore single-vision spectacles (control group) (n = 120) for 2 years. Spherical equivalent refractive error (SER), axial length (AL), pupil diameter (PD), and amplitud...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Can Cui, Xiujuan Li, Yong Lyu, Li Wei, Bingxin Zhao, Shiao Yu, Junbo Rong, Yanhui Bai, Aicun Fu
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/5c697c8dcc7f4aa0a582daf78025bded
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5c697c8dcc7f4aa0a582daf78025bded
record_format	dspace
spelling	oai:doaj.org-article:5c697c8dcc7f4aa0a582daf78025bded2021-11-21T12:23:58ZSafety and efficacy of 0.02% and 0.01% atropine on controlling myopia progression: a 2-year clinical trial10.1038/s41598-021-01708-22045-2322https://doaj.org/article/5c697c8dcc7f4aa0a582daf78025bded2021-11-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-01708-2https://doaj.org/toc/2045-2322Abstract Four hundred myopic children randomly received atropine 0.02% (n = 138) or 0.01% (n = 142) in both eyes once-nightly or only wore single-vision spectacles (control group) (n = 120) for 2 years. Spherical equivalent refractive error (SER), axial length (AL), pupil diameter (PD), and amplitude of accommodation (AMP) were measured every 4 months. After 2 years, the SER changes were − 0.80 (0.52) D, − 0.93 (0.59) D and − 1.33 (0.72) D and the AL changes were 0.62 (0.29) mm, 0.72 (0.31) mm and 0.88 (0.35) mm in the 0.02% and 0.01% atropine groups and control group, respectively. There were significant differences between changes in SER and AL in the three groups (all P < 0.001). The changes in SER and AL in the 2nd year were similar to the changes in the 1st year in the three groups (all P > 0.05). From baseline to 2 years, the overall decrease in AMP and increase in PD were not significantly different in the two atropine groups, whereas the AMP and PD in the control group remained stable (all P > 0.05). 0.02% atropine had a better effect on myopia control than 0.01% atropine, and its effects on PD and AMP were similar to 0.01% atropine. 0.02% or 0.01% atropine controlled myopia progression and AL elongation synchronously and had similar effects on myopia control each year.Can CuiXiujuan LiYong LyuLi WeiBingxin ZhaoShiao YuJunbo RongYanhui BaiAicun FuNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Can Cui Xiujuan Li Yong Lyu Li Wei Bingxin Zhao Shiao Yu Junbo Rong Yanhui Bai Aicun Fu Safety and efficacy of 0.02% and 0.01% atropine on controlling myopia progression: a 2-year clinical trial
description	Abstract Four hundred myopic children randomly received atropine 0.02% (n = 138) or 0.01% (n = 142) in both eyes once-nightly or only wore single-vision spectacles (control group) (n = 120) for 2 years. Spherical equivalent refractive error (SER), axial length (AL), pupil diameter (PD), and amplitude of accommodation (AMP) were measured every 4 months. After 2 years, the SER changes were − 0.80 (0.52) D, − 0.93 (0.59) D and − 1.33 (0.72) D and the AL changes were 0.62 (0.29) mm, 0.72 (0.31) mm and 0.88 (0.35) mm in the 0.02% and 0.01% atropine groups and control group, respectively. There were significant differences between changes in SER and AL in the three groups (all P < 0.001). The changes in SER and AL in the 2nd year were similar to the changes in the 1st year in the three groups (all P > 0.05). From baseline to 2 years, the overall decrease in AMP and increase in PD were not significantly different in the two atropine groups, whereas the AMP and PD in the control group remained stable (all P > 0.05). 0.02% atropine had a better effect on myopia control than 0.01% atropine, and its effects on PD and AMP were similar to 0.01% atropine. 0.02% or 0.01% atropine controlled myopia progression and AL elongation synchronously and had similar effects on myopia control each year.
format	article
author	Can Cui Xiujuan Li Yong Lyu Li Wei Bingxin Zhao Shiao Yu Junbo Rong Yanhui Bai Aicun Fu
author_facet	Can Cui Xiujuan Li Yong Lyu Li Wei Bingxin Zhao Shiao Yu Junbo Rong Yanhui Bai Aicun Fu
author_sort	Can Cui
title	Safety and efficacy of 0.02% and 0.01% atropine on controlling myopia progression: a 2-year clinical trial
title_short	Safety and efficacy of 0.02% and 0.01% atropine on controlling myopia progression: a 2-year clinical trial
title_full	Safety and efficacy of 0.02% and 0.01% atropine on controlling myopia progression: a 2-year clinical trial
title_fullStr	Safety and efficacy of 0.02% and 0.01% atropine on controlling myopia progression: a 2-year clinical trial
title_full_unstemmed	Safety and efficacy of 0.02% and 0.01% atropine on controlling myopia progression: a 2-year clinical trial
title_sort	safety and efficacy of 0.02% and 0.01% atropine on controlling myopia progression: a 2-year clinical trial
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/5c697c8dcc7f4aa0a582daf78025bded
work_keys_str_mv	AT cancui safetyandefficacyof002and001atropineoncontrollingmyopiaprogressiona2yearclinicaltrial AT xiujuanli safetyandefficacyof002and001atropineoncontrollingmyopiaprogressiona2yearclinicaltrial AT yonglyu safetyandefficacyof002and001atropineoncontrollingmyopiaprogressiona2yearclinicaltrial AT liwei safetyandefficacyof002and001atropineoncontrollingmyopiaprogressiona2yearclinicaltrial AT bingxinzhao safetyandefficacyof002and001atropineoncontrollingmyopiaprogressiona2yearclinicaltrial AT shiaoyu safetyandefficacyof002and001atropineoncontrollingmyopiaprogressiona2yearclinicaltrial AT junborong safetyandefficacyof002and001atropineoncontrollingmyopiaprogressiona2yearclinicaltrial AT yanhuibai safetyandefficacyof002and001atropineoncontrollingmyopiaprogressiona2yearclinicaltrial AT aicunfu safetyandefficacyof002and001atropineoncontrollingmyopiaprogressiona2yearclinicaltrial
_version_	1718419066484424704

Safety and efficacy of 0.02% and 0.01% atropine on controlling myopia progression: a 2-year clinical trial

Ejemplares similares